Track topics on Twitter Track topics that are important to you
Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...
NewsRE-DUAL PCI results offer favorable new safety data on Pradaxa. Large safety study compared dual therapy with Pradaxa to triple therapy with warfarin in people who have undergone percutaneous coro...
WEDNESDAY, Oct. 18, 2017 -- New anti-clotting drugs -- like Xarelto, Pradaxa and Eliquis -- aren't linked with a higher risk of bleeding than the older drug warfarin, a new study finds. Many patients ...
Monday, September 18th 2017 at 7:08am UTC The CHMP of the EMA has issued a positive opinion for an update of the Summary of Product Characteristics (SmPC) for Pradaxa® (dabigatran etexilate) The CHMP...
Bayer AG on Sunday said that results of its phase III study of the blood thinner Xarelto showed that it lowered the combined risk of stroke, cardiovascular death and heart attack in patients with chro...
Results from the pivotal Phase III COMPASS study found that the Xarelto (rivaroxaban) vascular dose (2.5mg…
Germany’s Bayer and Johnson & Johnson (J&J) of the US have won the third of three lawsuits involving bleeding risks of the blockbuster blood thinner Xarelto, which was developed and prod...
RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® dual therapy was used instead of warfarin triple therapy Both Pradaxa® doses tested in RE-DUAL PCI™ ha...
Johnson & Johnson unit Janssen Research & Development's supplemental new drug application for a 10-mg daily dose of Xarelto, -More-